The Ohio State University Comprehensive Cancer Center (OSUCCC) Pharmacoanalytical Shared Resource (PhASR) has been in development since 2004. PhASR provides bioanalytical method development, quantitative sample analysis, and pharmacokinetic/pharmacodynamic (PK/PD) experimental design and data analysis to support pre-clinical and clinical cancer drug development. PhASR's objectives are to provide: 1) high-quality, state-of-the-art analytical expertise and instrumentation for quantitation of drugs and metabolites in biological specimens at cost-competitive rates; 2) PK/PD data for incorporation into clinical decision-making; and 3) expertise in PK/PD study design and data interpretation to support submission of clinical protocols, grants, and publications. PhASR is directed by Dr. Kenneth K. Chan, with additional support from Technical Director, Dr. Mitch A. Phelps. An additional staff of 2.70 full-time employees provides support for sample processing, method development and PK/PD data analysis and modeling. Outstanding institutional support is provided by the OSUCCC and College of Pharmacy's Division of Pharmaceutics that houses the fully-equipped pharmaceutical research laboratories of Drs Chan and Phelps which comprise PhASR. Major equipment in PhASR includes 3 LC-MS systems and 2 stand-alone LC-UV systems ideally suited for drug quantitation and metabolite identification. These systems include a quadrupole-time-of-flight and two triple-quadrupole mass spectrometers, one of which is supported by an ultra-high pressure liquid chromatography system expandable for automated sample processing and high throughput enalysis. Additional LC-MS systems to develop and run biological correlative assays are available. By leveraging outstanding institutional partnerships, PhASR is able to offer its services to OSUCCC members at reduced rates. In the past 12 months PhASR staff has analyzed more than 2,600 samples and has logged nearly 1,700 hours for analytical method development and PK/PD experimental design and data analysis. Neariy 95% of this activity supported 27 members in 5 of the 6 programs within the OSUCCC. Recent highlights of work by PhASR researchers include design of an active flavopiridol dosing schedule and pharmacokinetic modeling of data from 8 clinical trials; development, validation and application of ultrasensitive assays (pM) to support clinical investigations of Bcl-2 and ribonucleotide reductase targeted antisense therapies (G3139 and GTI-2040); validation and application of methods for quantitation of low dose decitabine and resulting intracellular endogenous nucleoside and drug phosphates and global and regional DNA methylation; and pre-clinical pharmacokinetic and metabolism studies of the novel natural product, silvestrol, now in pre-clinical development by the OSUCCC and the NCI. In its short time as a developing resource, PhASR has made these and other significant contributions resulting in high impact publications, grant proposals and funding for OSUCCC investigators. Institutional support and OSUCCC investigators' recognition of the quality of PhASR capabilities and services have insured the continued growth and success of this highly valued shared resource.

Public Health Relevance

Ohio State University Comprehensive Cancer Center (OSUCCC) Pharmacoanalytical Shared Resource (PhASR) provides cost effective, high quality and state-of-the-art bioanalytical method development quantitative sample analysis, and pharmacokinetic/pharmacodynamic experimental design and data analysis to support pre-clinical and clinical cancer drug development

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-36
Application #
8555665
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-09-12
Project End
2015-11-30
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
36
Fiscal Year
2012
Total Cost
$126,378
Indirect Cost
$43,507
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Bolyard, Chelsea; Meisen, W Hans; Banasavadi-Siddegowda, Yeshavanth et al. (2017) BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy. Clin Cancer Res 23:1809-1819
Schuh, Elizabeth M; Portela, Roberta; Gardner, Heather L et al. (2017) Safety and efficacy of targeted hyperthermia treatment utilizing gold nanorod therapy in spontaneous canine neoplasia. BMC Vet Res 13:294
Kumar, Bhavna; Yadav, Arti; Brown, Nicole V et al. (2017) Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status. Oncotarget 8:14847-14859
Miller, Cecelia R; Ruppert, Amy S; Fobare, Sydney et al. (2017) The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget 8:25942-25954
Pearlman, Rachel; Frankel, Wendy L; Swanson, Benjamin et al. (2017) Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. JAMA Oncol 3:464-471
Farren, Matthew R; Hennessey, Rebecca C; Shakya, Reena et al. (2017) The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors. Mol Cancer Ther 16:417-427
Teng, Kun-Yu; Han, Jianfeng; Zhang, Xiaoli et al. (2017) Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. Mol Cancer Ther 16:312-322
Russell, Luke; Bolyard, Chelsea; Banasavadi-Siddegowda, Yeshavanth et al. (2017) Sex as a biological variable in response to temozolomide. Neuro Oncol 19:873-874
Terrazas, Cesar; de Dios Ruiz-Rosado, Juan; Amici, Stephanie A et al. (2017) Helminth-induced Ly6Chi monocyte-derived alternatively activated macrophages suppress experimental autoimmune encephalomyelitis. Sci Rep 7:40814
Saporito, Donika; Brock, Pamela; Hampel, Heather et al. (2017) Penetrance of a rare familial mutation predisposing to papillary thyroid cancer. Fam Cancer :

Showing the most recent 10 out of 2211 publications